RNA Drug Pipeline Accelerates with Over 20 Pharmaceutical Companies Developing Treatments
A new report reveals over 20 companies are developing more than 90 drug candidates using RNA interference technology. Several promising clinical trials commenced in June 2026.
The RNA interference (RNAi) therapeutic landscape is experiencing accelerated development, with over 20 pharmaceutical companies advancing more than 90 drug candidates, according to DelveInsight's "RNA Interference Pipeline Insight 2026" report. These candidates are in various stages of clinical and non-clinical development.
Significant clinical trial activity was reported in June 2026. Mirum Pharmaceuticals initiated a Phase 3 global trial for brelovitug to treat chronic hepatitis delta virus (HDV) infection. Fred Hutchinson Cancer Center began a Phase 2 trial investigating remdesivir for respiratory syncytial virus (RSV) infections in immunocompromised patients. Regeneron Pharmaceuticals is researching an experimental drug, ALN-CFB, for patients with paroxysmal nocturnal hemoglobinuria (PNH) experiencing anemia. Additionally, RiboX Therapeutics Ltd. is evaluating the safety and efficacy of RXRG001 for treating radiation-induced dry mouth.
Key players in the RNAi space identified in the report include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Dicerna Pharmaceuticals. Their ongoing research, focusing on therapies like inclisiran and vutrisiran, aims to address a range of conditions, from rare genetic disorders to oncological indications.
RNA interference (RNAi) is a biological process that uses small RNA molecules to silence specific genes. This mechanism is being leveraged to develop targeted therapeutics that can address the molecular roots of diseases. While the field is still evolving, it holds substantial promise for treating conditions previously lacking effective therapeutic options.